The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas
Open accessThe DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
The Activator Protein-1 (AP-1) transcription factor (TF) family, composed of a variety of members including c-JUN, c-FOS and ATF, is involved in mediating many biological processes such as proliferation, differentiation and cell death. Since their discovery, the role of AP-1 TFs in cancer development has been extensively analysed. Multiple in vitro and in vivo studies have highlighted the complexity of these TFs, mainly due to their cell-type specific homo- or hetero-dimerization resulting in diverse transcriptional response profiles. However, as a result of the increasing knowledge of the role of AP-1 TFs in disease, these TFs are being recognized as promising therapeutic targets for various malignancies. In this review, we focus on the impact of deregulated expression of AP-1 TFs in CD30-positive lymphomas including Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Histone Deacetylase Inhibitors Suppress the Induction of c-Jun and Its Target Genes Including COX-2
Yamaguchi, K., Lantowski, A., Dannenberg, A. J., & Subbaramaiah, K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503201200 · Cited by 80 · cited 1×
“Further investigations revealed that HDAC inhibitors suppress c-JUN binding to Cyclooxygenase-2 (COX-2), Cyclin D1, and Collagenase-1 promoter regions, thereby blocking transcription [43].”
BackgroundRetractedThe 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Signal transduction by the JNK group of MAP kinases
Davis, R. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00116-1 · Cited by 4,237 · cited 1×
“For example, c-JUN activation is regulated by Stress Activated Kinases (SAPKs), most commonly referred to as c-JUN N-terminal Kinases (JNKs) [26].”
BackgroundAP-1 as a regulator of cell life and death
Shaulian, E., & Karin, M. (2002) · Nature Cell Biology · doi:10.1038/ncb0502-e131 · Cited by 2,961 · cited 3×
“In summary, AP-1 TFs are regulated by dimer configuration, gene transcription, post-translational modifications and protein interactions [2].”
BackgroundAngel, P., Imagawa, M., Chiu, R., Stein, B., Imbra, R. J., Rahmsdorf, H. J., Jonat, C., Herrlich, P., & Karin, M. (1987) · Cell · doi:10.1016/0092-8674(87)90611-8 · Cited by 2,931 · cited 1×
“Activator Protein-1 (AP-1) was one of the first mammalian TFs to be identified [1].”
BackgroundThe Regulation of AP-1 Activity by Mitogen-activated Protein Kinases
Karin, M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16483 · Cited by 2,431 · cited 1×
“Initial investigations revealed that external stimuli influence the phosphorylation and differential expression patterns of AP-1 proteins [24,25].”
BackgroundAP-1: a double-edged sword in tumorigenesis
Eferl, R., & Wagner, E. F. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1209 · Cited by 2,242 · cited 3×
“Multiple studies have therefore highlighted the implication of AP-1 TFs in major cancer-related pathways, including inflammation, differentiation, cellular migration, metastasis, angiogenesis and wound healing [3].”
BackgroundInternational T-Cell Lymphoma Project (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4558 · Cited by 2,108
Zandi, E., Rothwarf, D. M., Delhase, M., Hayakawa, M., & Karin, M. (1997) · Cell · doi:10.1016/s0092-8674(00)80406-7 · Cited by 1,812
Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation.
Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van Antwerp, D., & Miyamoto, S. (1995) · Genes & Development · doi:10.1101/gad.9.22.2723 · Cited by 1,724 · cited 1×
“For example, JNK activation via inflammatory or stress-related cytokines results in the phosphorylation of JUN and the nuclear translocation of NF-κB [80].”
BackgroundRedox Regulation of Fos and Jun DNA-Binding Activity in Vitro
Abate, C., Patel, L., Rauscher, F. J., & Curran, T. (1990) · Science · doi:10.1126/science.2118682 · Cited by 1,573 · cited 1×
“In addition, NF-κB and AP-1 TFs share common mechanisms of activation as they appear to be simultaneously activated by the same stimuli [78,79].”
BackgroundSelective interaction of JNK protein kinase isoforms with transcription factors.
Gupta, S., Barrett, T., Whitmarsh, A. J., Cavanagh, J., Sluss, H. K., Dérijard, B., & Davis, R. J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00636.x · Cited by 1,338 · cited 1×
“Alternative forms of the three JNK proteins (JNK1, JNK2, JNK3) exist, with different abilities to bind and phosphorylate AP-1 family members [27,28].”
BackgroundGreen, M. R., Monti, S., Rodig, S. J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,305
AP-1 subunits: quarrel and harmony among siblings
Hess, J., Angel, P., & Schorpp-Kistner, M. (2004) · Journal of Cell Science · doi:10.1242/jcs.01589 · Cited by 1,302 · cited 1×
“The tumour-promoting agent 12-O-tetradecanoylphorbol-13-acetate (TPA) activates AP-1 enabling its binding to the TPA-response element (TRE) with the consensus sequence 5′-TGAG/CTCA-3′ [5] (Figure 1B).”
BackgroundThe jun proto-oncogene is positively autoregulated by its product, Jun/AP-1
Angel, P., Hattori, K., Smeal, T., & Karin, M. (1988) · Cell · doi:10.1016/0092-8674(88)90143-2 · Cited by 1,239 · cited 1×
“Mutations in this region abolished the induction of c-JUN mRNA [22].”
BackgroundRosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haioun, C., Greiner, T. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031074 · Cited by 1,101
Boyle, W. J., Smeal, T., Defize, L. H. K., Angel, P., Woodgett, J. R., Karin, M., & Hunter, T. (1991) · Cell · doi:10.1016/0092-8674(91)90241-p · Cited by 1,055 · cited 1×
“Five phosphorylation sites have been reported on serine and threonine residues of c-JUN, regulating its trans-activity by distinct mechanisms [29,30].”
Backgroundc-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities
Halazonetis, T. D., Georgopoulos, K., Greenberg, M. E., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90147-x · Cited by 1,035 · cited 1×
“JUN proteins can both homo- and hetero-dimerize, whereas FOS proteins only form hetero-dimers, which, particularly for JUN/FOS, are more stable and have greater transcriptional activity [9,10].”
BackgroundMatsusaka, T., Fujikawa, K., Nishio, Y., Mukaida, N., Matsushima, K., Kishimoto, T., & Akira, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.10193 · Cited by 959 · cited 1×
“Finally, the identification of both AP-1 and NF-κB binding sites in the promoter region of IL-6 and CXCL8 cemented the NF-κB/AP-1/IL-6/CXCL8 axis [24,76,77].”
BackgroundStein, H., Foss, H., Dürkop, H., Marafioti, T., Delsol, G., Pulford, K. A. F., Pileri, S. A., & Falini, B. (2000) · Blood · doi:10.1182/blood.v96.12.3681 · Cited by 949
Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ domain
Treier, M., Staszewski, L. M., & Bohmann, D. (1994) · Cell · doi:10.1016/s0092-8674(94)90502-9 · Cited by 923 · cited 1×
“Interestingly, c-FOS is degraded by the proteasome independently of its own ubiquitination marks [36,37], whereas c-JUN is only degraded in an ubiquitin-dependent manner [38].”
The anaplastic lymphoma kinase in the pathogenesis of cancer
Chiarle, R., Voena, C., Ambrogio, C., Piva, R., & Inghirami, G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2291 · Cited by 882
IL-6 in autoimmune disease and chronic inflammatory proliferative disease
Ishihara, K., & Hirano, T. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00027-8 · Cited by 807 · cited 1×
“Additionally, continuous production of IL-6 and CXCL8 results in the enhanced survival of lymphocytes, which further increases serum cytokine/chemokine levels [74,75].”
BackgroundPD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.4482 · Cited by 791
Smeal, T., Binetruy, B., Mercola, D. A., Birrer, M., & Karin, M. (1991) · Nature · doi:10.1038/354494a0 · Cited by 789 · cited 1×
“JNK-stimulated phosphorylation of c-JUN’s N-terminal domain at residues S63/S73 facilitates its physical interactions with co-activators, promoting the expression of target genes [31,32], whereas c-JUN phosphorylation on T91/T93 residues releases c-JUN target genes”
BackgroundRole of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
Ha, H., Debnath, B., & Neamati, N. (2017) · Theranostics · doi:10.7150/thno.15625 · Cited by 789 · cited 1×
“Furthermore, elevated levels of pro-inflammatory cytokines and chemokines, such as IL-6, a pro-inflammatory cytokine involved in haematopoiesis [72], and CXCL8, a chemokine responsible for the recruitment and activation of immune cells [73], maintain malignant proliferation.”
BackgroundBargou, R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M. Y., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119849 · Cited by 761 · cited 2×
“Furthermore, overexpression of a dominant negative IκB results in decreased nuclear NF-κB activity in HRS cells via dampening of proliferation and enhancement of apoptosis [68].”
BackgroundCrystal structure of the heterodimeric bZIP transcription factor c-Fos–c-Jun bound to DNA
Glover, J. N. M., & Harrison, S. C. (1995) · Nature · doi:10.1038/373257a0 · Cited by 735 · cited 1×
“Together, the leucine-zipper domain and the adjacent basic domain form a flexible and unique “scissor-shaped” alpha-helical structure [4].”
BackgroundAP-1 in mouse development and tumorigenesis
Jochum, W., Passegué, E., & Wagner, E. F. (2001) · Oncogene · doi:10.1038/sj.onc.1204389 · Cited by 733 · cited 1×
“Genetic manipulation of JUN and FOS proteins in mice have highlighted the critical and selective role of AP-1 TFs in development and tumour formation [51].”
BackgroundProlonged activation of jun and collagenase genes by tumour necrosis factor-α
Brenner, D. A., O'Hara, M., Angel, P., Chojkier, M., & Karin, M. (1989) · Nature · doi:10.1038/337661a0 · Cited by 717 · cited 2×
“, Tumour Necrosis Factor alpha (TNF-α) [53]), or cytokines (e.”
BackgroundChinenov, Y., & Kerppola, T. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204385 · Cited by 715 · cited 1×
“For instance, JUN/JUN and JUN/FOS recognise the TRE sequence, whereas ATF TFs bind to cAMP response elements (CRE) at the consensus site 5′-TGACGTCA-3′ (Figure 1B) [7].”
BackgroundJun-B differs in its biological properties from, and is a negative regulator of, c-Jun
Chiu, R., Angel, P., & Karin, M. (1989) · Cell · doi:10.1016/0092-8674(89)90754-x · Cited by 688 · cited 1×
“For example, JUNB/c-FOS hetero-dimers often dampen transcription, whereas c-JUN/c-FOS heterodimers frequently enhance c-JUN transforming abilities, highlighting the differential effects of the various AP-1 TFs [13].”
BackgroundThe biology of Hodgkin's lymphoma
Küppers, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2542 · Cited by 688 · cited 2×
“AP-1 family members are involved in a variety of mitogenic signalling pathways such as RAS/MAPK, PI3K/AKT/mTOR and JAK/STAT/MYC [23,88,124,170].”
BackgroundGreen, M. R., Rodig, S., Juszczynski, P., Ouyang, J., Sinha, P., O'Donnell, E., Neuberg, D., & Shipp, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1942 · Cited by 685 · cited 1×
“Interestingly, PD-L2 transcription is not enhanced in an AP-1-dependent manner even though PD-L2 is also overexpressed in HRS cells [109].”
BackgroundKallunki, T., Su, B., Tsigelny, I., Sluss, H. K., Dérijard, B., Moore, G., Davis, R., & Karin, M. (1994) · Genes & Development · doi:10.1101/gad.8.24.2996 · Cited by 642 · cited 1×
“Alternative forms of the three JNK proteins (JNK1, JNK2, JNK3) exist, with different abilities to bind and phosphorylate AP-1 family members [27,28].”
BackgroundMenin Interacts with the AP1 Transcription Factor JunD and Represses JunD-Activated Transcription
Agarwal, S. K., Guru, S. C., Heppner, C., Erdos, M. R., Collins, R. M., Park, S. Y., Saggar, S., Chandrasekharappa, S. C., Collins, F. S., Spiegel, A. M., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80967-8 · Cited by 627 · cited 1×
“Most notably, when the tumour suppressor Menin interacts with JUND, it inhibits its transcriptional activity, indicating that JUND might be involved in neoplastic growth suppression [14].”
BackgroundInterleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells.
Goldgaber, D., Harris, H. W., Hla, T., Maciag, T., Donnelly, R. J., Jacobsen, J. S., Vitek, M. P., & Gajdusek, D. C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7606 · Cited by 595 · cited 2×
“, interleukin-1 (IL-1) [54]), altogether supporting cell proliferation, growth and survival.”
BackgroundControl of cell cycle progression by c-Jun is p53 dependent
Schreiber, M., Kolbus, A., Piu, F., Szabowski, A., Mohle-Steinlein, U., Tian, J., Karin, M., Angel, P., & Wagner, E. F. (1999) · Genes & Development · doi:10.1101/gad.13.5.607 · Cited by 574 · cited 1×
“The reduction in p53, which consecutively leads to dampening of the cyclin-dependent kinase inhibitor (CDKI) p21, accelerates the transition from G1 to S phase [17].”
BackgroundIqbal, J., Wright, G., Wang, C., Rosenwald, A., Gascoyne, R. D., Weisenburger, D. D., Greiner, T. C., Smith, L., Guo, S., Wilcox, R. A., et al. (2014) · Blood · doi:10.1182/blood-2013-11-536359 · Cited by 552
MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets
Muslin, A. J. (2008) · Clinical Science · doi:10.1042/cs20070430 · Cited by 494
Crescenzo, R., Abate, F., Lasorsa, E., Tabbo’, F., Gaudiano, M., Chiesa, N., Di Giacomo, F., Spaccarotella, E., Barbarossa, L., Ercole, E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.006 · Cited by 443
Self-citationAvian sarcoma virus 17 carries the jun oncogene.
Maki, Y., Bos, T. J., Davis, C., Starbuck, M., & Vogt, P. K. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.2848 · Cited by 440 · cited 1×
“c-JUN and c-FOS were initially identified as retroviral onco-proteins (v-Jun and v-Fos) of the Avian sarcoma virus 17 (ASV17) and Finkel–Biskis–Jinkins murine sarcoma virus, respectively [49,50].”
BackgroundmiR-21 Gene Expression Triggered by AP-1 Is Sustained through a Double-Negative Feedback Mechanism
Fujita, S., Ito, T., Mizutani, T., Minoguchi, S., Yamamichi, N., Sakurai, K., & Iba, H. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.03.015 · Cited by 433 · cited 1×
“During early T lymphocyte activation, miRNA-21 is induced, which promotes the Mitogen-Activated Protein Kinase (MAPK)/Extracellular Signal-regulated Kinase (ERK) pathway and JNK signalling and enhances AP-1 activity [46,47].”
Backgroundc-Jun and JunB Antagonistically Control Cytokine-Regulated Mesenchymal–Epidermal Interaction in Skin
Szabowski, A., Maas-Szabowski, N., Andrecht, S., Kolbus, A., Schorpp-Kistner, M., Fusenig, N. E., & Angel, P. (2000) · Cell · doi:10.1016/s0092-8674(00)00178-1 · Cited by 428 · cited 1×
“c-JUN and the FOS protein family members positively regulate cellular proliferation, in comparison to JUNB, which negatively regulates proliferation [15].”
BackgroundMechanism of specificity in the Fos-Jun oncoprotein heterodimer
O'Shea, E. K., Rutkowski, R., & Kim, P. S. (1992) · Cell · doi:10.1016/0092-8674(92)90145-3 · Cited by 422 · cited 1×
“JUN proteins can both homo- and hetero-dimerize, whereas FOS proteins only form hetero-dimers, which, particularly for JUN/FOS, are more stable and have greater transcriptional activity [9,10].”
BackgroundImmunopathogenesis and therapy of cutaneous T cell lymphoma
Kim, E. J., Hess, S., Richardson, S. K., Newton, S., Showe, L. C., Benoit, B. M., Ubriani, R., Vittorio, C. C., Junkins-Hopkins, J. M., Wysocka, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24826 · Cited by 413
c-Jun and p53 Activity Is Modulated by SUMO-1 Modification
Müller, S., Berger, M., Lehembre, F., Seeler, J.-S., Haupt, Y., & Dejean, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.18.13321 · Cited by 400
Specificity through cooperation: BATF–IRF interactions control immune-regulatory networks
Murphy, T. L., Tussiwand, R., & Murphy, K. M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3470 · Cited by 399
Bakiri, L. (2000) · The EMBO Journal · doi:10.1093/emboj/19.9.2056 · Cited by 398 · cited 1×
“On the other hand, JUNB negatively regulates cell proliferation by inhibiting the progression into S phase via activation of the CDKI p16INK4a and repression of cyclin D1 [18,19].”
BackgroundThe essential role of MEKK3 in TNF-induced NF-κB activation
Yang, J., Lin, Y., Guo, Z., Cheng, J., Huang, J., Deng, L., Liao, W., Chen, Z., Liu, Z.-G., & Su, B. (2001) · Nature Immunology · doi:10.1038/89769 · Cited by 396
Mathas, S., Hinz, M., Anagnostopoulos, I., Krappmann, D., Lietz, A., Jundt, F., Bommert, K., Mechta‐Grigoriou, F., Stein, H., Dörken, B., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf389 · Cited by 375 · cited 1×
“In particular, JUNB or c-JUN expression protects cells from apoptosis, thereby enhancing cellular proliferation and colony formation [23,71,121,123,125].”
Background(2003) · PubMed · Cited by 355
Foss, F. M., Zinzani, P. L., Vose, J. M., Gascoyne, R. D., Rosen, S. T., & Tobinai, K. (2011) · Blood · doi:10.1182/blood-2010-05-231548 · Cited by 353 · cited 2×
“Leukaemic and Disseminated Disease [61,62] Adult T-cell Leukaemia/Lymphoma (ATLL)”
BackgroundJunB suppresses cell proliferation by transcriptional activation of p16INK4a expression
Passegue, E. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.2969 · Cited by 332 · cited 1×
“On the other hand, JUNB negatively regulates cell proliferation by inhibiting the progression into S phase via activation of the CDKI p16INK4a and repression of cyclin D1 [18,19].”
BackgroundYoshie, O., Fujisawa, R., Nakayama, T., Harasawa, H., Tago, H., Izawa, D., Hieshima, K., Tatsumi, Y., Matsushima, K., Hasegawa, H., et al. (2002) · Blood · doi:10.1182/blood.v99.5.1505 · Cited by 326
Vallois, D., Dobay, M. P. D., Morin, R. D., Lemonnier, F., Missiaglia, E., Juilland, M., Iwaszkiewicz, J., Fataccioli, V., Bisig, B., Roberti, A., et al. (2016) · Blood · doi:10.1182/blood-2016-02-698977 · Cited by 324 · cited 1×
“Activating mutations involved in the AP-1/MAPK pathway were detected in a fraction of AITL cases: three missense mutations of KRAS (G13D, A18D, and I36M) and two missense mutations of STAT3 (E616G and E616K), all of which result in constitutive activation of the AP-1 transcription factor c-FOS [140].”
BackgroundShaulian, E., Schreiber, M., Piu, F., Beeche, M., Wagner, E. F., & Karin, M. (2000) · Cell · doi:10.1016/s0092-8674(00)00193-8 · Cited by 295 · cited 1×
“For example, despite having been identified as a potent oncogene and tumour promoter, c-JUN is responsible for inducing apoptosis in UV-exposed cells [20].”
BackgroundSkinnider, B. F., Elia, A. J., Gascoyne, R. D., Patterson, B., Trumper, L., Kapp, U., & Mak, T. W. (2002) · Blood · doi:10.1182/blood.v99.2.618 · Cited by 288
Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells.
Mori, N., Fujii, M., Ikeda, S., Yamada, Y., Tomonaga, M., Ballard, D. W., & Yamamoto, N. (1999) · PubMed · doi:10.1182/blood.v93.7.2360 · Cited by 285
Chen, D., Wu, M., Li, Y., Chang, I., Yuan, Q., Ekimyan-Salvo, M., Deng, P., Yu, B., Yu, Y., Dong, J., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.02.003 · Cited by 280 · cited 1×
“Recent preclinical studies in mice have shown that this inhibitor reduces lymph node metastasis of oral cancer and targets stem cells in squamous cell carcinoma when combined with cisplatin, suggesting it may be efficacious in the treatment of some cancers [167,168].”
BackgroundGenomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.
Joos, S., Küpper, M., Ohl, S., von Bonin, F., Mechtersheimer, G., Bentz, M., Marynen, P., Mӧller, P., Pfreundschuh, M. G., Trümper, L. H. P., et al. (2000) · PubMed · Cited by 273
Hinz, M., Lemke, P., Anagnostopoulos, I., Hacker, C., Krappmann, D., Mathas, S., Dörken, B., Zenke, M., Stein, H., & Scheidereit, C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020062 · Cited by 266
deLeeuw, R. J., Zettl, A., Klinker, E., Haralambieva, E., Trottier, M., Chari, R., Ge, Y., Gascoyne, R. D., Chott, A., Müller–Hermelink, H., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.036 · Cited by 250 · cited 1×
“Enteropathy-associated T-cell lymphoma and hepatosplenic γδ T-cell lymphoma are extremely rare entities [62,110], which may account for the lack of literature describing the importance of AP-1 factors in these diseases [150,151].”
BackgroundAdvances in the understanding and management of angioimmunoblastic T‐cell lymphoma
De Leval, L., Gisselbrecht, C., & Gaulard, P. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08003.x · Cited by 247
B-cell Receptor Activation Induces BIC/miR-155 Expression through a Conserved AP-1 Element
Yin, Q., Wang, X., McBride, J., Fewell, C., & Flemington, E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708218200 · Cited by 232
Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1
Aikawa, Y., Morimoto, K., Yamamoto, T., Chaki, H., Hashiramoto, A., Narita, H., Hirono, S., & Shiozawa, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1412 · Cited by 214
Horie, R., Watanabe, T., Morishita, Y., Ito, K., Ishida, T., Kanegae, Y., Saito, I., Higashihara, M., Mori, S., Kadin, M. E., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205337 · Cited by 207
Micro RNA s play a central role in molecular dysfunctions linking inflammation with cancer
Tili, E., Michaille, J., & Croce, C. M. (2013) · Immunological Reviews · doi:10.1111/imr.12050 · Cited by 206 · cited 1×
“MicroRNAs (miRNAs), are small non-coding RNAs of about 19-23 base-pairs that mediate post-transcriptional silencing and also influence AP-1 activity [45].”
BackgroundPromoter Specificity and Biological Activity of Tethered AP-1 Dimers
Bakiri, L., Matsuo, K., Wisniewska, M., Wagner, E. F., & Yaniv, M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.13.4952-4964.2002 · Cited by 206 · cited 1×
“Thus, the dimerization partners of JUN influence its role in gene activation and cell cycle regulation [11,12].”
BackgroundDown-Regulation of c-Fos/c-Jun AP-1 Dimer Activity by Sumoylation
Bossis, G., Malnou, C. E., Farras, R., Andermarcher, E., Hipskind, R., Rodriguez, M., Schmidt, D., Muller, S., Jariel-Encontre, I., & Piechaczyk, M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.16.6964-6979.2005 · Cited by 195
Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas
Mao, X., Orchard, G., Lillington, D. M., Russell-Jones, R., Young, B. D., & Whittaker, S. J. (2003) · Blood · doi:10.1182/blood-2002-08-2434 · Cited by 194 · cited 3×
“In particular, JUNB or c-JUN expression protects cells from apoptosis, thereby enhancing cellular proliferation and colony formation [23,71,121,123,125].”
BackgroundOgawa, S., Lozach, J., Jepsen, K., Sawka-Verhelle, D., Perissi, V., Sasik, R., Rose, D. W., Johnson, R. S., Rosenfeld, M. G., & Glass, C. K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405786101 · Cited by 183
Steidl, C., Telenius, A., Shah, S. P., Farinha, P., Barclay, L., Boyle, M., Connors, J. M., Horsman, D. E., & Gascoyne, R. D. (2010) · Blood · doi:10.1182/blood-2009-12-257345 · Cited by 176
Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase.
Fuchs, S. Y., Dolan, L., Davis, R. J., & Ronai, Z. A. (1996) · PubMed · Cited by 168
Giri, R. S., Thaker, H. M., Giordano, T., Williams, J., Rogers, D., Sudersanam, V., & Vasu, K. K. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.10.031 · Cited by 167
Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells.
Schmid, C., Pan, L., Diss, T. C., & Isaacson, P. G. (1991) · PubMed · Cited by 159
Monje, P., Marinissen, M. J., & Gutkind, J. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.19.7030-7043.2003 · Cited by 147
Watanabe, M., Sasaki, M., Itoh, K., Higashihara, M., Umezawa, K., Kadin, M. E., Abraham, L. J., Watanabe, T., & Horie, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0925 · Cited by 147 · cited 14×
“The World Health Organisation classifies CHL and PTCL into sub-groups based on the presentation of the lymphoma and their clinical features [60–62] (Table 1).”
BackgroundInfluentialScheeren, F., Diehl, S., Smit, L., Beaumont, T., Naspetti, M., Bende, R., Blom, B., Karube, K., Ohshima, K., van Noesel, C. V., et al. (2008) · Blood · doi:10.1182/blood-2007-08-105643 · Cited by 146 · cited 1×
“The overexpression of constitutively active forms of either STAT5A or STAT5B in normal B cells leads to upregulation of the Tumour Necrosis Factor Receptor Superfamily 8 (TNFRSF8), also known as CD30, a cell membrane protein normally expressed by activated T and B cells [85].”
BackgroundEckerle, S., Brune, V., Döring, C., Tiacci, E., Bohle, V., Sundström, C., Kodet, R., Paulli, M., Falini, B., Klapper, W., et al. (2009) · Leukemia · doi:10.1038/leu.2009.161 · Cited by 137 · cited 1×
“The JAK/STAT pathway is commonly involved in maintaining elevated proliferation of malignant cells by interacting with TFs such as the AP-1 family members [83,84].”
BackgroundThe AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors
Shen, Q., Uray, I. P., Li, Y., Krisko, T. I., Strecker, T. E., Kim, H.-T., & Brown, P. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210643 · Cited by 135 · cited 1×
“It also showed an inhibitory effect on IL-2/IL-8 production, CD8-positive T-cells and Th1/Th2 cytokine mRNA expression in animal models for inflammatory disorders [161,162].”
BackgroundPDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas
Laimer, D., Dolznig, H., Kollmann, K., Vesely, P. W., Schlederer, M., Merkel, O., Schiefer, A. I., Hassler, M. R., Heider, S., Amenitsch, L., et al. (2012) · Nature Medicine · doi:10.1038/nm.2966 · Cited by 134 · cited 6×
“Treatment with Imatinib, a tyrosine kinase inhibitor, results in a decrease in tumour burden and increased survival of c-JUN and JUNB transgenic knock-out mice harbouring the constitutively active NPM–ALK fusion in CD4+ T cells [131].”
BackgroundInfluentialSelf-citationBaker, S. J., Kerppola, T. K., Luk, D., Vandenberg, M. T., Marshak, D. R., Curran, T., & Abate, C. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.10.4694 · Cited by 124
Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls
Jaffe, E. S., Nicolae, A., & Pittaluga, S. (2013) · Modern Pathology · doi:10.1038/modpathol.2012.181 · Cited by 124 · cited 7×
“In this review, we will present the current literature on the role AP-1 TFs play in lymphoid malignancies, focusing on CD30-positive lymphomas, specifically, Classical Hodgkin Lymphoma (CHL) and the Non-Hodgkin Lymphoma (NHL) sub-type peripheral T-cell lymphoma (PTCL) which constitutes a heterogeneous group of disease…”
InfluentialDifferential cytokine regulation by NF-κB and AP-1 in Jurkat T-cells
Khalaf, H., Jass, J., & Olsson, P.-E. (2010) · BMC Immunology · doi:10.1186/1471-2172-11-26 · Cited by 122 · cited 1×
“Additionally, continuous production of IL-6 and CXCL8 results in the enhanced survival of lymphocytes, which further increases serum cytokine/chemokine levels [74,75].”
BackgroundStaber, P. B., Vesely, P. W., Haq, N., Ott, R. G., Funato, K., Bambach, I., Fuchs, C. D., Schauer, S., Linkesch, W., Hrzenjak, A., et al. (2007) · Blood · doi:10.1182/blood-2007-02-071258 · Cited by 117 · cited 4×
“AP-1 family members are involved in a variety of mitogenic signalling pathways such as RAS/MAPK, PI3K/AKT/mTOR and JAK/STAT/MYC [23,88,124,170].”
BackgroundInfluentialSelf-citationImpact of Interleukin-6 in Hematological Malignancies
Burger, R. (2013) · Transfusion Medicine and Hemotherapy · doi:10.1159/000354194 · Cited by 116 · cited 1×
“Furthermore, elevated levels of pro-inflammatory cytokines and chemokines, such as IL-6, a pro-inflammatory cytokine involved in haematopoiesis [72], and CXCL8, a chemokine responsible for the recruitment and activation of immune cells [73], maintain malignant proliferation.”
BackgroundAmbrogio, C., Martinengo, C., Voena, C., Tondat, F., Riera, L., di Celle, P. F., Inghirami, G. G., & Chiarle, R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2655 · Cited by 116
Alfonso-Jaume, M., Bergman, M. R., Mahimkar, R., Cheng, S., Jin, Z. Q., Karliner, J. S., & Lovett, D. H. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00026.2006 · Cited by 114 · cited 2×
“For instance, SP100030 was the first group of inhibitors of AP-1 and NF-κB transcription activation in Jurkat cells [160,161].”
BackgroundAgnelli, L., Mereu, E., Pellegrino, E., Limongi, T., Kwee, I., Bergaggio, E., Ponzoni, M., Zamò, A., Iqbal, J., Piccaluga, P. P., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405555 · Cited by 111
Upstream promoter element of the human metallothionein-IIA gene can act like an enhancer element.
Haslinger, A., & Karin, M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8572 · Cited by 110 · cited 1×
“This TRE element was first discovered in the promoters of metallothionein IIa (hMTIIa) and simian virus 40 (SV40) [6].”
BackgroundNF-κB deregulation in Hodgkin lymphoma
Weniger, M. A., & Küppers, R. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.05.001 · Cited by 108 · cited 2×
“Mutations in IκB and/or constitutive activity of kinase receptors upstream of the signalling pathway result in NF-κB insensitivity to IκB [68,69].”
BackgroundATF3, an HTLV-1 bZip factor binding protein, promotes proliferation of adult T-cell leukemia cells
Hagiya, K., Yasunaga, J., Satou, Y., Ohshima, K., & Matsuoka, M. (2011) · Retrovirology · doi:10.1186/1742-4690-8-19 · Cited by 106
Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma
Weilemann, A., Grau, M., Erdmann, T., Merkel, O., Sobhiafshar, U., Anagnostopoulos, I., Hummel, M., Siegert, A., Hayford, C., Madle, H., et al. (2014) · Blood · doi:10.1182/blood-2014-08-594507 · Cited by 102 · cited 3×
“Accordingly, in ALCL, suppression of LCK, FYN, ITK, CD69, CD52, ICOS and NFATc2, in addition to induction of JUNB and MUM1/IRF4 transcription is also observed [126,135].”
BackgroundSelf-citationMathas, S., Kreher, S., Meaburn, K. J., Jöhrens, K., Lamprecht, B., Assaf, C., Sterry, W., Kadin, M. E., Daibata, M., Joos, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900912106 · Cited by 101 · cited 1×
“Given the activity of c-JUN, JUNB, FRA-2, and ATF-3 in ALCL, it is likely that other AP-1 activating factors play a role in lymphomagenesis [92,118].”
BackgroundSchleußner, N., Merkel, O., Costanza, M., Liang, H.-C., Hummel, F., Romagnani, C., Durek, P., Anagnostopoulos, I., Hummel, M., Jöhrens, K., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0045-9 · Cited by 98 · cited 4×
“However, recent studies have shed light on the involvement and role of AP-1 TFs in lymphoid malignancies [92,126,131].”
BackgroundInfluentialSelf-citationJanz, M., Hummel, M., Truß, M., Wollert‐Wulf, B., Mathas, S., Jöhrens, K., Hagemeier, C., Bommert, K., Stein, H., Dörken, B., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2694 · Cited by 97
Leventaki, V., Drakos, E., Medeiros, L. J., Lim, M. S., Elenitoba‐Johnson, K. S. J., Claret, F. X., & Rassidakis, G. Z. (2007) · Blood · doi:10.1182/blood-2006-11-059451 · Cited by 95 · cited 1×
“In particular, JUNB or c-JUN expression protects cells from apoptosis, thereby enhancing cellular proliferation and colony formation [23,71,121,123,125].”
BackgroundMalcolm, T. I. M., Villarèse, P., Fairbairn, C., Lamant, L., Trinquand, A., Hook, C. E., Burke, G. A. A., Brugières, L., Hughes, K., Payet‐Bornet, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms10087 · Cited by 94 · cited 1×
“Whilst molecular TCR rearrangements are seen in ALCL, the TCR is not expressed on the surface of ALCL cells [128].”
Self-citationConstitutive activation of transcription factor AP-1 in primary adult T-cell leukemia cells.
Mori, N., Fujii, M., Iwai, K., Ikeda, S., Yamasaki, Y., Hata, T., Yamada, Y., Tanaka, Y., Tomonaga, M., & Yamamoto, N. (2000) · PubMed · doi:10.1182/blood.v95.12.3915 · Cited by 91 · cited 1×
“On the other hand, in primary adult T-cell leukaemia/lymphoma (ATLL), strong constitutive activation of NF-κB and AP-1 was also identified [141,142].”
BackgroundAraghi, R. R., Bird, G. H., Ryan, J. A., Jenson, J. M., Godes, M., Pritz, J. R., Grant, R. A., Letai, A. G., Walensky, L. D., & Keating, A. E. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712952115 · Cited by 88 · cited 1×
“In addition, the utilisation of stapled peptides to disrupt protein–protein interactions has proven successful [159].”
BackgroundJunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis
Rassidakis, G. Z., Thomaides, A. X., Atwell, C., Ford, R. J., Jones, D., Claret, F.-X., & Medeiros, L. J. (2005) · Modern Pathology · doi:10.1038/modpathol.3800419 · Cited by 88 · cited 1×
“Similar to other CD30+ lymphomas, CTCLs, including cutaneous ALCL and Lymphomatoid Papulosis (LyP), show abnormal JUNB expression which correlates with both CD30 and MAPK/ERK pathway activity [137,138].”
ResultStructural Basis of Alternative DNA Recognition by Maf Transcription Factors
Kurokawa, H., Motohashi, H., Sueno, S., Kimura, M., Takagawa, H., Kanno, Y., Yamamoto, M., & Tanaka, T. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00708-09 · Cited by 85 · cited 1×
“Interestingly, the crystal structure of MAF family members, bound to their respective DNA binding sites, revealed a unique bZIP structure that enables recognition of a long palindromic sequence referred to as the MAF recognition element (MARE) (Figure 1B) [8].”
BackgroundHassler, M. R., Pulverer, W., Lakshminarasimhan, R., Redl, E., Hacker, J., Garland, G. D., Merkel, O., Schiefer, A., Simonitsch‐Klupp, I., Kenner, L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.018 · Cited by 82
Self-citationSignaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
Liu, W. R., & Shipp, M. A. (2017) · Blood · doi:10.1182/blood-2017-06-781989 · Cited by 82
CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features
Bisig, B., de Reyniès, A., Bonnet, C. M., Sujobert, P., Rickman, D. S., Marafioti, T., Delsol, G., Lamant, L., Gaulard, P., & de Leval, L. (2013) · Haematologica · doi:10.3324/haematol.2012.081935 · Cited by 81 · cited 2×
“JUNB in turn activates CD30 transcription resulting in a positive feedback loop [135].”
BackgroundNakayama, T., Hieshima, K., Arao, T., Jin, Z. H., Nagakubo, D., Shirakawa, A.-K., Yamada, Y., Fujii, M., Oiso, N., Kawada, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210984 · Cited by 81
Xia, Y., Wang, J., Liu, T.-J., Yung, W. K. A., Hunter, T. R., & Lu, Z. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.005 · Cited by 80 · cited 1×
“Furthermore, reversible protein acetylation is also implicated in AP-1 regulation, as osmotic stress downregulates c-JUN via the histone deacetylase, HDAC3-dependent transcriptional repression [42].”
BackgroundBossis, G., Ferrara, P., Acquaviva, C., Jariel-Encontre, I., & Piechaczyk, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.20.7425-7436.2003 · Cited by 77 · cited 1×
“Interestingly, c-FOS is degraded by the proteasome independently of its own ubiquitination marks [36,37], whereas c-JUN is only degraded in an ubiquitin-dependent manner [38].”
BackgroundTAK1-dependent Activation of AP-1 and c-Jun N-terminal Kinase by Receptor Activator of NF-κB
Lee, S.-W., Han, S.-I., Kim, H.-H., & Lee, Z.-H. (2002) · BMB Reports · doi:10.5483/bmbrep.2002.35.4.371 · Cited by 77 · cited 2×
“This is supported by the fact that many genes require the concomitant activation of AP-1 and NF-κB, explaining the shared stimuli resulting in their activation and cooperative nature [79,81].”
BackgroundFerrara, P., Andermarcher, E., Bossis, G., Acquaviva, C., Brockly, F., Jariel‐Encontre, I., & Piechaczyk, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206266 · Cited by 77 · cited 1×
“Interestingly, c-FOS is degraded by the proteasome independently of its own ubiquitination marks [36,37], whereas c-JUN is only degraded in an ubiquitin-dependent manner [38].”
BackgroundSignaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies
Xia, Y., Medeiros, L. J., & Young, K. H. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.09.002 · Cited by 75 · cited 3×
“These findings suggest a potential AP-1/PD-1 axis which could be exploited as a future therapeutic option for CHL, especially since PD-1 and its ligands have already highlighted the clinical efficacy of targeted immunotherapy [105].”
BackgroundTurner, S. D., Yeung, D., Hadfield, K., Cook, S. J., & Alexander, D. R. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.09.007 · Cited by 75 · cited 2×
“demonstrated that NPM–ALK, via the RAS/MAPK pathway and calcium signalling, induces transcription via AP-1/NFAT composite binding sites, mimicking activated TCR signalling [124].”
BackgroundSelf-citationJohnston, I., Spence, H. J., Winnie, J. N., McGarry, L., Vass, J. K., Meagher, L., Stapleton, G., & Ozanne, B. W. (2000) · Oncogene · doi:10.1038/sj.onc.1203927 · Cited by 74 · cited 1×
“c-JUN regulates cell cycle progression in a dual fashion by inhibiting the p53 tumour suppressor and by stimulating cyclin D1 [16].”
BackgroundThe interaction between HIF-1 and AP-1 transcription factors in response to low oxygen
Laderoute, K. R. (2005) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2005.03.005 · Cited by 72 · cited 1×
“Similarly, AP-1 TFs interact with hypoxia-inducible factor 1 alpha (HIF1a), establishing a link between AP-1 and angiogenesis [55].”
BackgroundSchwering, I., Bräuninger, A., Distler, V., Jesdinsky, J., Diehl, V., Hansmann, M., Rajewsky, K., & Küppers, R. (2003) · Molecular Medicine · doi:10.1007/bf03402041 · Cited by 71
Lollies, A., Hartmann, S., Schneider, M., Bracht, T., Weiß, A. L., Arnolds, J., Klein‐Hitpass, L., Sitek, B., Hansmann, M.-L., Küppers, R., et al. (2017) · Leukemia · doi:10.1038/leu.2017.203 · Cited by 69 · cited 6×
“This novel oncogenic STAT–BATF-3/JUN–MYC signalling axis seems to be essential for HRS cell survival (Figure 2) [88].”
BackgroundInfluentialc-Jun Homodimers Can Function as a Context-Specific Coactivator
Grondin, B., Lefrançois, M., Tremblay, M. R., Saint-Denis, M., Haman, A., Waga, K., Bédard, A., Tenen, D. G., & Hoang, T. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00936-06 · Cited by 67 · cited 1×
“Thus, the dimerization partners of JUN influence its role in gene activation and cell cycle regulation [11,12].”
BackgroundWatanabe, M., Ogawa, Y., Ito, K., Higashihara, M., Kadin, M. E., Abraham, L. J., Watanabe, T., & Horie, R. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63690-5 · Cited by 67 · cited 2×
“Furthermore, the discovery of an AP-1 site in the CD30 MS suggested that relief of suppression of the CD30 promoter is mediated via JUNB [100].”
BackgroundMacLaren, A., Black, E. J., Clark, W., & Gillespie, D. A. F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.20.9006-9018.2004 · Cited by 64 · cited 1×
“Furthermore, c-JUN-deficient cells were found to undergo premature senescence as a result of spontaneous DNA damage, suggesting that c-JUN plays a role in stimulating DNA repair [21].”
BackgroundActivation of the serum response factor by p65/NF‐kappaB.
Franzoso, G., Carlson, L. M., Brown, K., Daucher, M., Bressler, P. B., & Siebenlist, U. K. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00706.x · Cited by 63 · cited 1×
“Furthermore, the response of AP-1 TFs is strikingly enhanced when NF-κB subunits are present, as is highlighted by the p65 subunit of NF-κB which acts as an accessory protein for AP-1 TF dimerization [82].”
BackgroundMao, X., Orchard, G. E., Mitchell, T. J., Oyama, N., Russell‐Jones, R., Vermeer, M. H., Willemze, R., van Doorn, R., Tensen, C. P., Young, B. D., et al. (2008) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2007.00924.x · Cited by 62 · cited 7×
“To date, most studies have focussed on immunohistochemical findings, although genomic amplification of JUNB with concomitant increased expression, leads to deregulated AP-1 activity in CTCL [138].”
BackgroundResultInfluentialKamide, D., Yamashita, T., Araki, K., Tomifuji, M., Tanaka, Y., Tanaka, S., Shiozawa, S., & Shiotani, A. (2016) · Cancer Science · doi:10.1111/cas.12914 · Cited by 61 · cited 1×
“Recent preclinical studies in mice have shown that this inhibitor reduces lymph node metastasis of oral cancer and targets stem cells in squamous cell carcinoma when combined with cisplatin, suggesting it may be efficacious in the treatment of some cancers [167,168].”
BackgroundKreher, S., Bouhlel, M. A., Cauchy, P., Lamprecht, B., Li, S., Grau, M., Hummel, F., Köchert, K., Anagnostopoulos, I., Jöhrens, K., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406985111 · Cited by 60 · cited 5×
“In turn, BATF-3, together with JUN family proteins and IRF4, binds to AP-1/IRF4 composite elements (AICEs) present in the promoter region of MYC as well as of various other target genes (Figure 2) [88,92,126].”
BackgroundInfluentialGene expression profiling of peripheral T-cell lymphoma including γδ T-cell lymphoma
Miyazaki, K., Yamaguchi, M., Imai, H., Kobayashi, T., Tamaru, S., Nishii, K., Yuda, M., Shiku, H., & Katayama, N. (2008) · Blood · doi:10.1182/blood-2008-07-166363 · Cited by 60 · cited 1×
“Enteropathy-associated T-cell lymphoma and hepatosplenic γδ T-cell lymphoma are extremely rare entities [62,110], which may account for the lack of literature describing the importance of AP-1 factors in these diseases [150,151].”
BackgroundRegulation of T lymphocyte activation by microRNA-21
Wang, L., He, L., Zhang, R., Liu, X., Ren, Y., Liu, Z., Zhang, X., Cheng, W., & Hua, Z.-C. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.02.004 · Cited by 56 · cited 1×
“During early T lymphocyte activation, miRNA-21 is induced, which promotes the Mitogen-Activated Protein Kinase (MAPK)/Extracellular Signal-regulated Kinase (ERK) pathway and JNK signalling and enhances AP-1 activity [46,47].”
Backgroundc-Jun Expression and Activation are Restricted to CD30+ Lymphoproliferative Disorders
Drakos, E., Leventaki, V., Schlette, E. J., Jones, D. M., Lin, P., Medeiros, L. J., & Rassidakis, G. Z. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213412.25935.e4 · Cited by 54 · cited 5×
“Indeed, unsupervised transcriptome clustering of PTCL-NOS correlates with CD30 expression: the CD30-positive PTCL-NOS group features high expression of the transcription factors JUNB and MUM1/IRF4, whereas these are largely absent in the majority of CD30-negative cases.”
BackgroundInfluentialChen, H., Tsou, H., Chang, C.-H., & Tang, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038378 · Cited by 53 · cited 2×
“, Hepatocyte growth factor (HGF) [52]), onco-proteins (e.”
Ball, D. P., Lewis, A. M., Williams, D., Resetca, D., Wilson, D. J., & Gunning, P. T. (2016) · Oncotarget · doi:10.18632/oncotarget.7838 · Cited by 50 · cited 1×
“However, recent progress has been made in targeting TFs through novel chemistries and protein structure-guided design strategies [157,158].”
BackgroundJuilland, M., Gonzalez, M., Erdmann, T., Banz, Y., Jevnikar, Z., Hailfinger, S., Tzankov, A., Grau, M., Lenz, G., Novak, U., et al. (2016) · Blood · doi:10.1182/blood-2015-07-655647 · Cited by 47 · cited 12×
“Most notably, when the tumour suppressor Menin interacts with JUND, it inhibits its transcriptional activity, indicating that JUND might be involved in neoplastic growth suppression [14].”
BackgroundInfluentialUchihashi, S., Fukumoto, H., Onoda, M., Hayakawa, H., Ikushiro, S., & Sakaki, T. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037952 · Cited by 46 · cited 2×
“(Tokyo, Japan) and Kitasato University, Japan [156].”
Salvat, C., Jariel‐Encontre, I., Acquaviva, C., Ōmura, S., & Piechaczyk, M. (1998) · Oncogene · doi:10.1038/sj.onc.1201922 · Cited by 42 · cited 1×
“An essential repression mechanism for AP-1 is its rapid degradation by the proteasome [35].”
BackgroundMeijer, C. A., Haen, P. A. A. L., van Dijk, R. A., Hira, M., Hamming, J. F., van Bockel, J. H., & Lindeman, J. H. N. (2011) · Clinical Science · doi:10.1042/cs20110234 · Cited by 41
The heterogeneous landscape of ALK negative ALCL
Mereu, E., Pellegrino, E., Scarfò, I., Inghirami, G. G., & Piva, R. (2017) · Oncotarget · doi:10.18632/oncotarget.14503 · Cited by 41
Atsaves, V., Lekakis, L. J., Drakos, E., Leventaki, V., Ghaderi, M., Baltatzis, G., Chioureas, D., Jones, D. M., Feretzaki, M., Liakou, C., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13079 · Cited by 41 · cited 1×
“In particular, JUNB or c-JUN expression protects cells from apoptosis, thereby enhancing cellular proliferation and colony formation [23,71,121,123,125].”
BackgroundNomenclature of CD molecules from the Tenth Human Leucocyte Differentiation Antigen Workshop
Clark, G. J., Stockinger, H. S. J., BALDERAS, R. S., van Zelm, M. C., Zola, H., Hart, D. N. J., & Engel, P. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2015.38 · Cited by 41 · cited 1×
“CD proteins are expressed on the surface of a variety of cells including lymphocytes and leukocytes of the immune system [93].”
BackgroundExpression of CCR9 in HTLV‐1+ T cells and ATL cells expressing Tax
Nagakubo, D., Jin, Z. H., Hieshima, K., Nakayama, T., Shirakawa, A., Tanaka, Y., Hasegawa, H., Hayashi, T., Tsukasaki, K., Yamada, Y., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22483 · Cited by 36
Giri, R. S., Thaker, H. M., Giordano, T., Chen, B., Nuthalapaty, S., Vasu, K. K., & Sudarsanam, V. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.04.038 · Cited by 35 · cited 1×
“Several other preclinical compounds have also been developed, although their clinical usefulness is hampered by low specificity, high IC50 values in the μM range, or a lack of oral bioavailability [160,164,169].”
BackgroundXia, Y., Yang, W., Bu, W., Ji, H., Zhao, X., Zheng, Y., Lin, X., Li, Y., & Lu, Z. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.475442 · Cited by 34 · cited 2×
“Initial investigations revealed that external stimuli influence the phosphorylation and differential expression patterns of AP-1 proteins [24,25].”
BackgroundBuchan, S. L., & Al‐Shamkhani, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045244 · Cited by 33
Watanabe, M., Itoh, K., Togano, T., Kadin, M. E., Watanabe, T., Higashihara, M., & Horie, R. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.10.007 · Cited by 32
He, W., Wu, Y., Tang, X., Xia, Y., He, G., Min, Z., Li, C., Xiong, S., Shi, Z., Lu, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6797 · Cited by 29 · cited 1×
“More recently, HDAC inhibitors have been reported to transcriptionally suppress both c-JUN and FRA-1 and mechanistically block c-JUN/FRA-1 dimerization, affecting neuroblastoma cell growth [44].”
BackgroundTsai, L. N., Ku, T. K. S., Salib, N. K., & Crowe, D. L. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01489-07 · Cited by 29 · cited 1×
“JNK-stimulated phosphorylation of c-JUN’s N-terminal domain at residues S63/S73 facilitates its physical interactions with co-activators, promoting the expression of target genes [31,32], whereas c-JUN phosphorylation on T91/T93 residues releases c-JUN target genes”
BackgroundExpression and function of FRA2/JUND in cutaneous T-cell lymphomas.
Nakayama, T., Higuchi, T., Oiso, N., Kawada, A., & Yoshie, O. (2012) · PubMed · Cited by 28
Atsaves, V., Zhang, R., Ruder, D., Pan, Y., Leventaki, V., Rassidakis, G. Z., & Claret, F. X. (2015) · Leukemia · doi:10.1038/leu.2015.127 · Cited by 28 · cited 1×
“AP-1 family members are involved in a variety of mitogenic signalling pathways such as RAS/MAPK, PI3K/AKT/mTOR and JAK/STAT/MYC [23,88,124,170].”
BackgroundMolecular genetics of peripheral T-cell lymphomas
Piccaluga, P. P., Tabanelli, V., & Pileri, S. A. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1522-1 · Cited by 26 · cited 1×
“Peripheral T-cell Lymphoma/Non-Hodgkin Lymphoma (NHL) [56–62] Nodal Lymphoma [56,57,62] Anaplastic Large Cell Lymphoma (ALCL)”
BackgroundPapoudou‐Bai, A., GOUSSIA, A. C., Batistatou, A. K., Stefanou, D., Malamou‐Mitsi, V., & Kanavaros, P. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1034704 · Cited by 22 · cited 1×
“This finding is in agreement with another study using immunohistochemistry in primary patient tissue, which showed a positive correlation between the expression of JUN family members and proliferation markers [153].”
ResultOrganization of the promoter region of the human NF-IL6 gene
Yang, Y., Parés-Matos, E. I., Tesmer, V. M., Dai, C., Ashworth, S., Huai, J., & Bina, M. (2002) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(02)00401-3 · Cited by 20 · cited 1×
“Finally, the identification of both AP-1 and NF-κB binding sites in the promoter region of IL-6 and CXCL8 cemented the NF-κB/AP-1/IL-6/CXCL8 axis [24,76,77].”
BackgroundBenharroch, D., Dima, E., Levy, A., Ohana-Malka, O., Ariad, S., Prinsloo, I., Mejirovsky, E., Sacks, M., & Gopas, J. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009053553 · Cited by 19 · cited 1×
“Despite a lack of understanding of the contribution of CD15 expression to the pathobiology of CHL, this antigen serves as a diagnostic marker [103].”
BackgroundOhana-Malka, O., Ozer, J., Prinsloo, I., Benharroch, D., & Gopas, J. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1095411 · Cited by 11 · cited 1×
“reported that binding of the CD15 antigen, induced nuclear translocation of c-JUN and a significant increase in AP-1 DNA binding activity [104].”
Background
Cited by
Single-cell biological network inference using a heterogeneous graph transformer
Ma, A., Wang, X., Li, J., Wang, C., Xiao, T., Liu, Y., Cheng, H., Wang, J., Li, Y., Chang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36559-0 · Cited by 184
Metadata
- Authors
- Garces de los Fayos Alonso, I., Liang, H.-C., Turner, S., Lagger, S., Merkel, O., & Kenner, L.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2018-03-28
- Volume
- 10
- Issue
- 4
- Pages
- 93
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2794898956
- Cited by
- 169
- References
- 150
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.